Related Experiment Video
Updated: Jul 11, 2026
06:01
A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
Published on: August 18, 2015
Thrombolysis for acute ischemic stroke: future directions.
James F Meschia1, Thomas G Brott
1Department of Neurology, Mayo Clinic, Jacksonville, FL 32224, USA. meschia.james@mayo.edu
Summary
Intravenous tissue plasminogen activator is the standard for acute ischemic stroke treatment. Future research should focus on combination therapies and improved reperfusion to enhance outcomes without increasing hemorrhage risks.
Area of Science:
- Neuroscience
- Cardiovascular Medicine
- Pharmacology
Background:
- Intravenous tissue plasminogen activator (tPA) is the current standard for acute ischemic stroke.
- Previous neuroprotective agents tested as monotherapies showed limited success.
- Preclinical trials of combination therapies with thrombolytics yielded mixed but promising results.
Purpose of the Study:
- To review the current landscape of acute ischemic stroke treatment.
- To explore the potential of combination therapies for improving stroke outcomes.
- To identify future directions for neuroprotective and thrombolytic agent development.
Main Methods:
- Review of preclinical and clinical trial data on thrombolytics and neuroprotective agents.
- Analysis of factors contributing to the success or failure of previous therapeutic strategies.
- Discussion of emerging trends in stroke treatment, including intra-arterial thrombolysis and advanced neuroimaging.
Main Results:
- Combination therapies involving thrombolytics and agents like citicoline, dizocilpine, nimodipine, and tirilizad showed encouraging preclinical results.
- Lessons learned from failed monotherapy trials emphasize the need for refined combination strategies.
- Advancements in neuroimaging offer potential for personalized thrombolytic therapy.
Conclusions:
- Future stroke treatment development should prioritize combination therapies to improve reperfusion rates while minimizing intracranial hemorrhage.
- Further investigation into newer fibrinolytics, combination antithrombotics, and intra-arterial thrombolysis is warranted.
- Tailored application of thrombolytic therapy, guided by neuroimaging, is a key future direction.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
01:15Ischemic Stroke ll: Pathophysiology
An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Hemorrhagic Stroke ll: Pathophysiology
A hemorrhagic stroke develops when a cerebral blood vessel ruptures, allowing blood to escape into the surrounding brain tissue, as in intracerebral hemorrhage (ICH), or into the subarachnoid space, as in subarachnoid hemorrhage (SAH). Because the skull is a rigid compartment, the sudden presence of extravascular blood rapidly increases intracranial pressure and compresses adjacent neural structures, leading to immediate tissue injury and impaired cerebral perfusion.Mass Effect and Primary...